Towards A Better Tomorrow: How Suven Life Sciences Yielded 4925% Returns

If you had ₹1 lakh invested in Suven in October 2012, then you could have had ₹50 lakhs in profits today! This multibagger gave its investors 4925% returns in just 10 years. Here’s a closer look at the company.

⚗️ Stock Name: Suven Life Sciences Ltd.
⚗️ NSE: $SUVEN

🌱 About The Company
Suven Life Sciences Limited, incorporated in 1989, is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders.

The company has been working towards developing new molecules or compounds in the complex Central Nervous System (CNS) indications where there is a high unmet medical need, growing patient populations and possible commercialisation options. Presently, the company operates 2 R&D centres in the state of Telangana. It has a research team of 110 employees out of which 7 are PhDs and 103 are M.Sc

📝 Projects
Presently, the company has a total of 15 molecules in its development and clinical pipeline, out of which 11 are in development phases and 4 have reached clinical phases. No molecules have reached a commercial stage and so the company has no revenue from these molecules in various development phases.

Suven has a wholly owned subsidiary, Suven Neurosciences, Inc., USA, which focuses on clinical development activities of Suven molecules from phase 2 Proof-of-Concept (POC) studies.

👣 Keeping Memories Alive
The company invested ₹71 crores towards R&D expenses in FY21. The company has spent ₹300 crores on clinical trials and ₹610 crores on development efforts of molecules to date. The goal is to be the leading biopharmaceutical company focused on the treatment of dementia, a condition characterised by a significant decline in mental capacity and impaired daily function.

💰 Stock Value
On October 12, 2012, the company’s shares were trading at ₹1.40, while they were priced at ₹70.35 as of October 11, 2022.